{
    "clinical_study": {
        "@rank": "11528", 
        "arm_group": [
            {
                "arm_group_label": "Dalfampridine", 
                "arm_group_type": "Experimental", 
                "description": "Dalfampridine will be provided at an oral dose of 10mg every 12 hours, for 4 weeks."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo will be administered orally every 12 hours, for a 4 week period."
            }
        ], 
        "brief_summary": {
            "textblock": "Investigators expect there will be improvement in walking speed and steadiness after taking\n      Dalfampridine, thereby improving activities of daily living and enhancing social and\n      occupational functions for patients with spinocerebellar ataxia."
        }, 
        "brief_title": "Dalfampridine and Gait in Spinocerebellar Ataxias", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Spinocerebellar Ataxias Type 1", 
            "Spinocerebellar Ataxias Type 2", 
            "Spinocerebellar Ataxias Type 3", 
            "Spinocerebellar Ataxias Type 6"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Ataxia", 
                "Machado-Joseph Disease", 
                "Spinocerebellar Ataxias", 
                "Spinocerebellar Degenerations"
            ]
        }, 
        "detailed_description": {
            "textblock": "Twenty spinocerebellar ataxia patients will be randomized to receive either Dalfampridine or\n      placebo over a total period of 10 weeks.  After entering the study, patients will return\n      every 2 weeks for evaluation.  After five weeks, intervention will be stopped and patient\n      will enter a 2-week wash out period where they do not take any drug.  Then, patients will be\n      given the opposite treatment (Dalfampridine or placebo) and this \"crossover\" study will be\n      performed for another 4 weeks.  Investigators expect there will be improvement in walking\n      speed and steadiness after taking Dalfampridine, thereby improving activities of daily\n      living and enhancing social and occupational functions."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Individuals at age 18 years or older.\n\n          -  Individuals who can provide the informed consent\n\n          -  Genetic confirmed definite spinocerebellar ataxias (SCA)\n\n          -  Able to complete two trials of the timed 25-foot walk at screening\n\n        Exclusion Criteria:\n\n          -  Patients who has severe ataxia and unable to ambulate.\n\n          -  Any orthopedic condition that would affect motor performance.\n\n          -  Patients with secondary ataxia from general medical disorders\n\n          -  Individuals who have major psychiatric disorders that prevents compliance\n\n          -  History of epilepsy\n\n          -  Patients with active drug or alcohol use or dependence that would interfere with\n             adherence to study requirements\n\n          -  Inability or unwillingness of subject or legal guardian/representative to give\n             written informed consent."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01811706", 
            "org_study_id": "20121107", 
            "secondary_id": "1133511"
        }, 
        "intervention": [
            {
                "arm_group_label": "Dalfampridine", 
                "description": "Dalfampridine will be provided at an oral dose of 10mg every 12 hours, for 4 weeks.", 
                "intervention_name": "Dalfampridine", 
                "intervention_type": "Drug", 
                "other_name": "Dalfampridine"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo will be administered orally every 12 hours, for a 4 week period.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "4-Aminopyridine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "October 11, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Gainesville", 
                    "country": "United States", 
                    "state": "Florida", 
                    "zip": "32607"
                }, 
                "name": "University of Florida"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Therapeutic Effect of Dalfampridine on Gait Incoordination in Spinocerebellar Ataxias- A Randomized, Double-blinded, Placebo-controlled, Crossover Clinical Trial", 
        "other_outcome": [
            {
                "description": "This is a blood test to monitor compliance by looking at Dalfampridine plasma level.", 
                "measure": "Dalfampridine plasma level", 
                "safety_issue": "No", 
                "time_frame": "week 4 and week 10"
            }, 
            {
                "description": "Patients will report on any adverse events they experienced that may or may not be due to treatment so that we may monitor safety.", 
                "measure": "Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "Weeks 2, 4, 6, 8, 10"
            }
        ], 
        "overall_official": {
            "affiliation": "University of Florida", 
            "last_name": "Guangbin Xia, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "The patient is directed to one end of a clearly marked 25-foot course and is instructed to walk 25 feet as quickly as possible, but safely. The time is calculated from the initiation of the instruction to start and ends when the patient has reached the 25-foot mark.  Patients may use walking assistance devices if needed.", 
                "measure": "Change in Timed 25 Feet Walking Test (T25FW)", 
                "safety_issue": "No", 
                "time_frame": "Screening and week 10"
            }, 
            {
                "description": "Biomechanical Assessment of Gait is a sensitive, quantitative movement analysis system. The analysis includes walking velocity, stride length, step width, double support and single support times, and center of mass displacement.", 
                "measure": "Change in Biomechanical Assessment of Gait (BAG)", 
                "safety_issue": "No", 
                "time_frame": "Screening and week 10"
            }, 
            {
                "description": "For 20 seconds, patients will stand on a pad that measures sway and tests balance, once with eyes open and once with eyes closed.", 
                "measure": "Change in Balance Test (BT)", 
                "safety_issue": "No", 
                "time_frame": "Screening and week 10"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01811706"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "SARA is a clinical scale including 8 items that are related to gait, stance, sitting, speech, finger-chase test, nose-finger test, fast alternating movements and heel-shin test.", 
                "measure": "Change in Scale of Assessment and Rating of Ataxia (SARA)", 
                "safety_issue": "No", 
                "time_frame": "Screening and week 10"
            }, 
            {
                "description": "Karnofsky Performance Scale (KPS) will be used to measure functional status.  It was designed to measure the level of patient activity and medical care requirements. It is a general measure of patient independence.", 
                "measure": "Change in Karnofsky Performance Scale (KPS)", 
                "safety_issue": "No", 
                "time_frame": "Screening and week 10"
            }, 
            {
                "description": "The WHOQOL questionnaire is an international cross-culturally comparable quality of life assessment instrument. It assesses the individual's perceptions in the context of their culture and value systems, and their personal goals, standards and concerns.", 
                "measure": "Change in World Health Organization Quality of Life (WHOQOL) Questionnaire", 
                "safety_issue": "No", 
                "time_frame": "Screening and week 10"
            }
        ], 
        "source": "University of Florida", 
        "sponsors": {
            "collaborator": {
                "agency": "Acorda Therapeutics", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "University of Florida", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}